Literature DB >> 19050056

Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Katherine Wesseling-Perry1, Renata C Pereira, Hejing Wang, Robert M Elashoff, Shobha Sahney, Barbara Gales, Harald Jüppner, Isidro B Salusky.   

Abstract

CONTEXT: Fibroblast growth factor (FGF)-23 is produced in bone, and circulating levels are markedly elevated in patients with end-stage kidney disease, but the relationship between plasma levels of FGF-23 and bone histology in dialysis patients with secondary hyperparathyroidism is unknown.
OBJECTIVE: The aim of the study was to evaluate the correlation between plasma levels of FGF-23 and bone histology in pediatric patients with end-stage kidney disease who display biochemical evidence of secondary hyperparathyroidism.
DESIGN: We performed a cross-sectional analysis of the relationship between plasma FGF-23 levels and bone histomorphometry.
SETTING: The study was conducted in a referral center. STUDY PARTICIPANTS: Participants consisted of forty-nine pediatric patients who were treated with maintenance peritoneal dialysis and who had serum PTH levels (1st generation Nichols assay) greater than 400 pg/ml. INTERVENTION: There were no interventions. MAIN OUTCOME MEASURE: Plasma FGF-23 levels and bone histomorphometry were measured.
RESULTS: No correlation existed between values of PTH and FGF-23. Bone formation rates correlated with PTH (r = 0.44; P < 0.01), but not with FGF-23. Higher FGF-23 concentrations were associated with decreased osteoid thickness (r = -0.49; P < 0.01) and shorter osteoid maturation time (r = -0.48; P < 0.01).
CONCLUSIONS: High levels of FGF-23 are associated with improved indices of skeletal mineralization in dialyzed pediatric patients with high turnover renal osteodystrophy. Together with other biomarkers, FGF-23 measurements may indicate skeletal mineralization status in this patient population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050056      PMCID: PMC2646517          DOI: 10.1210/jc.2008-0326

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Severe bone disease and low bone mineral density after juvenile renal failure.

Authors:  Jaap W Groothoff; Martin Offringa; Berthe L F Van Eck-Smit; Mariken P Gruppen; Nicole J Van De Kar; Eric D Wolff; Marc R Lilien; Jean Claude Davin; Hugo S A Heymans; Friedo W Dekker
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

2.  Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.

Authors:  Isidro B Salusky; William G Goodman; Beatriz D Kuizon; Jeffrey R Lavigne; Richard J Zahranik; Barbara Gales; He-Jing Wang; Robert M Elashoff; Harald Jüppner
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.

Authors:  M C Monier-Faugere; Z Geng; H Mawad; R M Friedler; P Gao; T L Cantor; H H Malluche
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

6.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.

Authors:  Giorgio Coen; Ermanno Bonucci; Paola Ballanti; Alessandro Balducci; Santo Calabria; Giulia A Nicolai; Maria Stephanie Fischer; Francesca Lifrieri; Micaela Manni; Massimo Morosetti; Eleonora Moscaritolo; Daniela Sardella
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

8.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

9.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

10.  Pathogenic role of Fgf23 in Dmp1-null mice.

Authors:  Shiguang Liu; Jianping Zhou; Wen Tang; Rochelle Menard; Jian Q Feng; L D Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-17       Impact factor: 4.310

View more
  64 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Evaluation of hypophosphatemia: lessons from patients with genetic disorders.

Authors:  Justine Bacchetta; Isidro B Salusky
Journal:  Am J Kidney Dis       Date:  2011-11-09       Impact factor: 8.860

3.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

Review 4.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

Review 5.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

6.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

7.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 8.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

Review 9.  Do osteocytes contribute to phosphate homeostasis?

Authors:  Jian Q Feng; Ling Ye; Susan Schiavi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-07       Impact factor: 2.894

Review 10.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.